anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses an application of benserazide hydrochloride in preparing a medicament for preventing and/or treating diseases caused by respiratory syncytial virus. Benserazide hydrochloride is a small molecule compound, CC thereof  50  It was 159.7. Mu.M. The invention discovers for the first time that the benserazide hydrochloride can inhibit the reproduction of the respiratory syncytial virus in a dose-dependent manner, and the IC of the benserazide hydrochloride  50  (median inhibitory concentration) was 0.76. Mu.M, and the Selection Index (SI) was about 210. The benserazide hydrochloride is a low-toxicity and high-efficiency medicament for resisting the respiratory syncytial virus.
The embodiments herein disclose method of synthesizing a composition of controlled drug (antibiotics) release for the treatment of peri-implantitis and periodontal infections which damages the Osseo-integrated dental implant and generates a loss of supporting bone. The combination of metronidazole and amoxicillin overcomes a wide range of pathogens associated with peri-implantitis. A localized biodegradable controlled drug delivery composition is synthesized for treatment of dental and implants infections (peri-implantisis). The system comprises polymer and antibiotics (metronidazole and amoxicillin). The system burst releases antibiotics in the first hours after administration, followed by a controlled release of the antibiotics for a time period up of 3 weeks. The antibiotic concentration is maintained in a suitable therapeutic range. An analysis after 14 days illustrates the elimination of the bacterial biofilm and bactericidal property of the composition.
FIELD: medicine, phytotherapy. SUBSTANCE: invention relates to the development of agent of natural origin showing an antidepressant effect. The proposed agent comprises fenestrate Saint-John's-wort herb powder or dried herb extract, blood-red hawthorn flowers or fruits powder, oat seeds powder, water-soluble chitosan and a filling agent. Agent is made as tablets. Agent promotes to overcome stress states, enhances body resistance against unfavorable factors of environment, stimulates nervous system and improves the circulation in brain, heart and other organs. EFFECT: enhanced effectiveness, valuable medicinal properties of agent. 2 cl, 1 ex
PURPOSE:To obtain a new phosphoric acid diester useful as an effective component for sun protection cosmetics, being highly safe for skin and having UV preventing effect with high remaining ability and excellent persistency on skin. CONSTITUTION:A phosphoric acid diester of the formula I[R1 is at least an acyl having 1 benzene ring (preferably p-methoxycinnamoyl, etc.); R2 is a 2-12C alkylene; L is a 2-40C alkyl or a R1-O-R2 group; M is H or an alkali metal ion, etc.; n is valence of M]. E.g. a compound of the formula II, etc. The compound of the formula I is obtained, e.g. by reacting a carboxylic acid having at least 1 benzene ring with a diol having 2-12C alkylene to obtain a monoester derivative, which is reacted with phosphorus oxychloride and then salt-exchanged or neutralized.
VIMOVO is contraindicated in patients with known hypersensitivity to naproxen, esomeprazole magnesium, substituted benzimidazoles, or to any of the excipients. 

VIMOVO is contraindicated in patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients [see Warnings and Precautions (5.8, 5.13)]. Hypersensitivity reactions, eg, angioedema and anaphylactic reaction/shock, have been reported with esomeprazole use. 

VIMOVO is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery [see Warnings and Precautions (5.1)]. 

VIMOVO is contraindicated in patients in the late stages of pregnancy [see Warnings and Precautions (5.10) and  Use in Specific Populations (8.1)].
The loss of the Y chromosome (ChrY), also known as LOY, is a common genetic alteration observed in men. It occurs in non-neoplastic cells as an age-related change as well as in neoplastic cells of various cancer types. While well-documented in humans, LOY has not been extensively studied in non-human mammals. In this study, we developed simple digital PCR-based assays to assess the copy number of ChrY relative to the X chromosome (ChrX) and chromosome 8 (Chr8) to evaluate ChrY numerical alterations in male canine DNA specimens. Using these assays, we analyzed non-neoplastic leukocytes from 162 male dogs without hematopoietic neoplasia to investigate the occurrence of age-related LOY in non-neoplastic leukocytes. Additionally, we examined 101 tumor DNA specimens obtained from male dogs diagnosed with various types of lymphoma and leukemia to determine whether copy number alterations of the ChrY occur in canine hematopoietic cancers. Analysis of the 162 non-neoplastic leukocyte DNA specimens from male dogs of varying ages revealed a consistent ∼1:1 ChrY:ChrX ratio. This suggests that age-related LOY in non-neoplastic leukocytes is rare or absent in dogs. Conversely, a decreased or increased ChrY:ChrX ratio was detected in canine neoplastic leukocytes at varying frequencies across different canine hematopoietic malignancies (P = 0.01, Fisher's exact test). Notably, a higher incidence of LOY was observed in more aggressive cancer types. To determine if this relative LOY to ChrX was caused by changes in ChrY or ChrX, we further analyzed their relative copy numbers using Chr8 as a reference. Loss of ChrX relative to Chr8 was found in 21% (9/41) of B-cell lymphomas and 6% (1/18) of non-T-zone/high-grade T-cell lymphomas. In contrast, a subset (29%, 4/14) of T-cell chronic lymphocytic leukemia showed gain of ChrX relative to Chr8. Notably, no relative LOY to Chr8 was detected indolent hematopoietic cancers such as T-zone lymphoma (0/9) and chronic lymphocytic leukemia of B-cell (0/11) and T-cell origins (0/14). However, relative LOY to Chr8 was present in more aggressive canine hematopoietic cancers, with incidences of 24% (10/41) in B-cell lymphoma, 44% (8/18) in non-T-zone/high-grade T-cell lymphoma, and 75% (6/8) in acute leukemia. This study highlights both similarities and differences in LOY between human and canine non-neoplastic and neoplastic leukocytes. It underscores the need for further research into the role of ChrY in canine health and disease, as well as the significance of LOY across various species.
Vitiligo is a commonly acquired pigmentary disease characterized by the progressive destruction of melanocytes. The role of adipose tissue in vitiligo remains unclear. To investigate the role of adipose tissue in the pathogenesis of vitiligo, 50 patients newly diagnosed with vitiligo and 40 age- and sex-matched healthy controls were enrolled, and fat mass and distribution using dual-energy X-ray absorptiometry (DXA) and serum adipokine levels using enzyme-linked immunosorbent assay were assessed. The trunk and whole-body fat mass and the trunk/limb fat mass ratio were significantly higher in patients with vitiligo. Higher leptin and resistin levels and lower adiponectin levels were observed. Positive correlation of the trunk fat mass index with vitiligo area scoring index scores (r = 0.38, p = 0.0071) was found. Additionally, plasma adiponectin levels were negatively correlated with vitiligo disease activity scores (r = -0.307, p < 0.05). Receiver operating characteristic curve analysis showed that the percentage of limb lean tissue mass, trunk/limb fat mass ratio, and serum adipokine levels achieved a high area under the curve score for distinguishing patients with vitiligo from healthy controls. In conclusion, the incidence of central obesity and adipokine dysregulation was higher in patients with vitiligo. The potential role of adipose tissue in the pathogenesis of vitiligo should be emphasized.
The invention relates to the technical field of biomedicine, in particular to a canine coronavirus attenuated strain and application thereof. The canine coronavirus low virulent strain is CCV14, and the preservation number is CGMCC NO:18507. An application of a canine coronavirus low virulent strain in the preparation of a medicament for treating and/or preventing diseases caused by canine coronavirus. The CV14 strain provided by the invention has no disease to dogs, has good immunogenicity, and can provide good immune protection to strong virus attacks of canine coronavirus. The low virulent strain can be prepared into single vaccine or combined vaccine, can effectively prevent diseases caused by canine coronavirus, and can also be applied to preparation of reagents or kits for treating, diagnosing or detecting the diseases caused by the canine coronavirus. The canine coronavirus attenuated vaccine strain has the advantages of stable heredity, lasting immunity, good immune effect, safety, reliability, long storage life and the like.
The schedule for vaccination will be Days 1, 4, 8, 15, 29, 57, 85, 113, 141, and 169. All study injections will be given intramuscularly and co-administered with poly-ICLC by a trained healthcare provider. It is anticipated that the PCV will be administered concurrently with nivolumab in patients enrolled in Cohort #1 Muscle Invasive Bladder Cancer. Adjuvant nivolumab is considered standard of care in this patient population. Concurrent administration with adjuvant nivolumab is anticipated but not required.
The efficacy of SEROQUEL XR in the treatment of schizophrenia was demonstrated in 1 short-term, 6-week, fixed-dose, placebo-controlled trial of inpatients and outpatients with schizophrenia (n=573) who met DSM IV criteria for schizophrenia. SEROQUEL XR (once daily) was administered as 300 mg on Day 1, and the dose was increased to either 400 mg or 600 mg by Day 2, or 800 mg by Day 3. The primary endpoint was the change from baseline of the Positive and Negative Syndrome Scale (PANSS) total score at the end of treatment (Day 42). SEROQUEL XR doses of 400 mg, 600 mg and 800 mg once daily were superior to placebo in the PANSS total score at Day 42.

In a longer-term trial, clinically stable adult outpatients (n=171) meeting DSM-IV criteria for schizophrenia who remained stable following 16 weeks of open-label treatment with flexible doses of SEROQUEL XR (400 mg/day-800 mg/day) were randomized to placebo or to continue on their current SEROQUEL XR (400 mg/day-800 mg/day) for observation for possible relapse during the double-blind continuation (maintenance) phase. Stabilization during the open-label phase was defined as receiving a stable dose of SEROQUEL XR and having a CGI-S≤4 and a PANSS score ≤60 from beginning to end of this open-label phase (with no increase of ≥10 points in PANSS total score). Relapse during the double-blind phase was defined in terms of a ≥30% increase in the PANSS Total score, or CGI-Improvement score of ≥6, or hospitalization due to worsening of schizophrenia, or need for any other antipsychotic medication. Patients on SEROQUEL XR experienced a statistically significant longer time to relapse than did patients on placebo.
Gamma aminobutyric acid (GABA) is a potent inhibitory neurotransmitter that binds to hetero-oligomeric receptors in the mammalian brain. In a previous study, we documented specific GABA binding to isolated rat hepatocytes which resulted in inhibition of hepatocyte proliferation. The purpose of the present study was to define the nature of hepatic GABA A  receptors and document their expression during rapid liver growth (post-partial hepatectomy). Polymerase chain reactions (PCR) with gene-specific primers derived from published sequences were performed with marathon-ready human and rat liver cDNA. Two GABA A  receptor subunit types (β3 and ε) were expressed in the human liver and one (β3) in the rat liver. PCR amplification of the human GABA A  receptor β3 subunit produced a single product (m.w. 53-59 kDa). In the case of the ε subunit, two PCR products were identified. Following partial hepatectomy, GABA A  receptor β3 subunit expression inversely correlated with regenerative activity (r=−0.527, p=0.006). In conclusion, these results indicate that in the human liver, GABA A  receptors consist of the β3 and ε subunit types whereas in the rat liver, only the β3 subunit type is expressed. The results also support the hypothesis that GABAergic activity serves to maintain hepatocytes in a quiescent state.
The invention discloses a production method of magnetic compound cosmetic material, and relates to a beautification apparatus. The invention is characterized in that the apparatus has the method that non vulcanized rubber is rolled; and the rubber and compounding agent are mixed and smelted. Magnetic non vulcanized rubber is rolled; and magnetic powder is added in the non vulcanized rubber which is mixed and smelted, and is smelted. The magnetic non vulcanized rubber is rolled to pieces. The magnetic non vulcanized rubber pieces are vulcanized through vulcanizing roll. Far infrared ceramic powders are coated on the magnetic non vulcanized rubber pieces which are vulcanized. According to the requirement, the magnetic non vulcanized rubber pieces which are vulcanized are cut into a fixed shape. The invention has the advantages that the cost is low, the operation is simple, because the product of the invention has magnetic field and far infrared ray, when the invention is stuck on the face, the skin of the face accepts the effect of the magnetic field and the far infrared ray, the potential of the human body is activated, the ability of metabolism is improved, the old cells can be replaced faster by the new cells of the skin, and the skin appears delicate, smooth, and lustrous.
Patients will receive an injection of GM-K562 cell vaccine every 3 weeks for at least 6 months. Some patients may receive treatment for up to 1 year. After 1 year, some patients may receive treatment as in arm I. NOTE: Study Arm B is not available to newly accrued and enrolled subjects based on the interim analysis directing all new subjects to the combination of Interferon + sargramostim (Arm A).
Placebo administered orally BID for 14 days followed by 14 days with no study drug (28 day cycles). Participants will receive BSC according to institutional guidelines. Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit. This arm is contingent on the data from the phase 2 arm.
The invention relates to the technical field of medicines, and particularly relates to a freeze-dried powder injection for dissolving thrombosis, and a preparation method thereof. The invention provides an FGFC1 freeze-dried powder injection capable of dissolving the thrombosis. The freeze-dried powder injection is composed of FGFC1, a co-solvent and a freeze-drying excipient. A weight ratio of the FGFC1 to the co-solvent is 1 : 0.1-10; and a weight ratio of the GFC1 to the freeze-drying excipien is 1 : 1-100. The invention also provides the preparation method of the FGFC1 freeze-dried powder injection. The FGFC1 freeze-dried powder injection provided by the invention has the characteristics of good re-dissolubility, stable quality and good compatible stability with conventional transfusion, and can completely meet clinical medication requirements.
VONJO can cause worsening thrombocytopenia. VONJO dosing was reduced due to worsening thrombocytopenia in 2% of patients with pre-existing moderate to severe thrombocytopenia (platelet count <100 x 10 9/L). VONJO dosing was reduced due to worsening thrombocytopenia in 2% of patients with pre-existing severe thrombocytopenia (platelet count <50 x 10 9/L). 

Monitor platelet count prior to VONJO treatment and as clinically indicated during treatment [see Dosage and Administration ( 2.2)] . Interrupt VONJO in patients with clinically significant worsening of thrombocytopenia that lasts for more than 7 days. Restart VONJO at 50% of the last given dose once the toxicity has resolved. If toxicity recurs hold VONJO. Restart VONJO at 50% of the last given dose once the toxicity has resolved [see Dosage and Administration ( 2.5)] .
PURPOSE:An agent for suppressing cancerous metastasis, suppressing selectively only metastasis ability of tumor cell, being expected to have improved effects especially on malignant tumor having high metastasis property, without exerting ban influence on cell multiplication at all, contaning an S- or O-beta-D-xyloside compoud as an active ingredient. CONSTITUTION:A beta-D-xyloside compound shown by the formula (X is O, or S; R is 1-8C alkyl) is used as an agent for suppressing cancerous metastasis. The compound shown by the formula disturbs proteoglycan existing on the surface of tumor cell, has effect on great change in molecular structure and configuration on the surface of tumor cell, and shows extremely improved suppressing effect on cancerous metastasis. Namely, since it has no bad influence on cell multiplications, and suppresses selectively only metastasis ability if tumor cell, it has no side effects such as bone marrow disorder, cardiotoxicity in an ordinary carcinostatic agent (e.g., alkylating agent, etc.). It is expected to have improved effect especially on malignant tumor (e.g., malignant melanoma, fibrosarcoma, lymphosarcoma, etc.) having high metastasis property.
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer. Recent studies indicated that cancer-associated adipocytes (CAAs) play crucial roles in tumor progression; however, the precise mechanism remains unknown. Here, we analyzed specific exosomal microRNAs (miRNA) signatures derived from pancreatic CAAs to investigate their role in cancer progression.
METHODS: CAAs were generated by co-culturing human adipocytes with human pancreatic cancer cells, and exosomes were isolated from the CAA-conditioned medium (CAA-CM). Small RNA-seq analysis was used to identify differentially expressed miRNAs in these exosomes. The effects of miRNAs on cell proliferation, migration/invasion, and drug sensitivity were examined. Luciferase reporter assays, real-time polymerase chain reaction, and western blotting were performed to investigate the molecular mechanisms of the miRNAs. The clinical relevance of the miRNAs was investigated using publicly available data and our cohort of patients with PDAC.
RESULTS: miR-199a-3p expression was significantly increased in CAA-CM-derived exosomes. CAA-derived exosomes transferred miR-199a-3p to pancreatic cancer cells. Transfection with miR-199a-3p increased the proliferation, invasion, migration, and drug resistance of pancreatic cancer cells by downregulating SOCS7, increasing STAT3 phosphorylation, and upregulating SAA1 expression. High tissue miR-199a-3p expression is correlated with poor prognosis in patients with PDAC. Liquid biopsies revealed that exosomal miR-199a-3p could accurately differentiate patients with PDAC from healthy controls. Multivariate survival analysis indicated that miR-199a is an independent prognostic factor for PDAC.
CONCLUSION: miR-199a-3p in CAA-derived exosomes contributes to the malignant transformation of pancreatic cancer via the SOCS7/STAT3/SAA1 pathway, suggesting its potential as a biomarker and therapeutic target for PDAC.
A control method for a reinforcement learning system includes following operations. The reinforcement learning system obtains training data relating to an interaction system. The interaction system interacts with a reinforcement learning agent. A neural network model is utilized by the reinforcement learning agent for selecting sequential actions from a set of candidate actions. The neural network model is trained to maximize cumulative rewards collected by the reinforcement learning agent in response to the sequential actions. During training of the neural network model, auxiliary rewards of the cumulative rewards are provided to the reinforcement learning agent according to a comparison between symptom inquiry actions of the sequential actions and diagnosed symptoms in the training data.
Persistent foot odor and itchiness are common symptoms of tinea pedis, significantly disrupting the daily life of those affected. The cuticular barrier at the site of the tinea pedis is thickened, which impedes the effective penetration of antifungal agents. Additionally, fungi can migrate from the skin surface to deeper tissues, posing challenges in the current clinical treatment for tinea pedis. To effectively treat tinea pedis, we developed a platform of bilayer gelatin methacrylate (GelMA) microneedles (MNs) loaded with salicylic acid (SA) and FK13-a1 (SA/FK13-a1@GelMA MNs). SA/FK13-a1@GelMA MNs exhibit pH- and matrix metalloproteinase (MMP)-responsive properties for efficient drug delivery. The MNs are designed to deliver salicylic acid (SA) deep into the stratum corneum, softening the cuticle and creating microchannels. This process enables the antibacterial peptide FK13-a1 to penetrate through the stratum corneum barrier, facilitating intradermal diffusion and exerting antifungal and anti-inflammatory effects. In severe cases of tinea pedis, heightened local pH levels and MMP activity further accelerate drug release. Our research demonstrates that SA/FK13-a1@GelMA MNs are highly effective against Trichophyton mentagrophytes, Trichophyton rubrum, and Candida albicans. They also reduced stratum corneum thickness, fungal burden, and inflammation in a guinea pig model of tinea pedis induced by T. mentagrophytes. Furthermore, it was discovered that SA/FK13-a1@GelMA MNs exhibit excellent biocompatibility. These findings suggest that SA/FK13-a1@GelMA MNs have significant potential for the clinical treatment of tinea pedis as well as other fungal skin disorders.
PROBLEM TO BE SOLVED: To obtain a new monoterpene-based compound separated/collected from cultured products by microorganisms (especially Actinomyces) and excellent in physiological activity, especially in antitumor action and antibacterial action. SOLUTION: This new monoterpene-based compound is expressed by formula I (wherein R1 is H or CH3; and R2 is CH20H or CO2CH3) and is e.g. a compound of formula II. The compound of formula I is obtained e.g. by culturing microorganisms producing the compound of formula I which belong e.g. to Nocardia and by collecting the compound of formula I from cultured products. The compound of formula I is produced e.g. by Nocardia brasiliensis IFM 0667 strain (FERM BP-6727) and is recognized to be also produced by other cell lines belonging to Nocardia. The compound of formula I can be produced by a chemically synthetic method as well.
Oral lesions in OLP are chronic ,rarely undergo spontaneous remission, are potentially premalignant and are often a source of morbidity. recent study does not support that non reticular OLP are more predisposed to malignant change. Moreover , immunosuppressive therapy did not influence the risk for oral cancer. in general ,all treatment should be aimed at eliminating precancerous lesions ,alleviating symptoms ,and potentially decreasing the risk of malignant transformation. Although the cause of OLP is unknown , it is generally considered to be an immunologically mediated process that microscopically resembles a hypersensitivity reaction .it is characterized by an intense T cell infiltrate localized to epithelium-connective tissue interface. the purpose of the study is to determined the efficacy of free soft tissue graft in treatment of precancerous and symptomatic lesions of OLP. so removal of the lesions up to submucosa will be done. the graft sliced from healthy mucosa also up to submucosa . then graft will be sutured in position.

According to other authors, basal epithelial layers of the graft remain intact and represent the focus of reepithelialization. new epithelial cell migrate over the basal membrane and appear to guide it and by proliferation ,will generate new epithelium. so the wound is re-epithelialized by proliferation of surrounding healthy epithelial cell, therefore, not contaminated by modified antigens of the cell membrane that are theoretically responsible for lymphocyte aggression so the healthy graft remains free of lesions and appears clinically healthy.